Core Insights - 九州通 reported strong financial performance for the first three quarters of 2025, with revenue of 119.33 billion yuan, a year-on-year increase of 5.20%, and a net profit attributable to shareholders of 1.975 billion yuan, up 16.46% [1] - The company is actively implementing its "Three New and Two Digital" strategy, focusing on new products, new retail, new medical services, digitalization, and real estate securitization [1] Financial Performance - In Q3 2025, 九州通 achieved revenue of 38.22 billion yuan and a net profit of 530 million yuan, representing year-on-year growth of 5.41% and 8.46%, respectively [1] - The net profit for Q3 showed a quarter-on-quarter increase of 11.39%, while the non-recurring net profit increased by 16.49% [1] Business Development - The new product strategy has proven effective, with total brand promotion sales reaching 14.73 billion yuan in the first three quarters, driven by a 15.26% increase in pharmaceutical agency revenue [2] - The medical beauty business grew significantly, with a year-on-year increase of 45.84%, and the number of cooperative service institutions exceeding 11,500 [2] New Retail Strategy - The "Good Medicine Master" franchise plan has accelerated, with a total of 33,275 direct and franchise pharmacies by the end of Q3, and franchise store sales growing by 43.40% [2] - B2B e-commerce revenue reached 15.53 billion yuan, a year-on-year increase of 19.68%, with over 600,000 registered users on the Jiujiu platform [2] New Medical Strategy - The "Jiu Medical Clinic" membership stores exceeded 3,000, with plans to reach 10,000 in three years [3] - The introduction of over 490 new products in the supply chain has led to a 69% quarter-on-quarter increase in sales of clinic-exclusive products [3] Digitalization and REITs - 九州通 invested 229 million yuan in R&D in the first three quarters, with 1,591 technical personnel, and implemented 34 projects including AI warehouse picking and smart logistics [3] - The company's REITs project has seen a 43.28% increase since its listing, with a 100% rental rate for initial assets in Shanghai, Hangzhou, and Chongqing [3] Future Development - The chairman emphasized the commitment to deepening the "Three New and Two Digital" strategy and accelerating the development of high-margin businesses [4] - The company is exploring the replication of the REITs model for more quality warehouse assets to optimize its capital structure [4]

Financial Performance - In the first three quarters of 2025, the company achieved revenue of 119.33 billion yuan (+5.20% year-on-year) and a net profit attributable to shareholders of 1.98 billion yuan (+16.46%) [1] - For Q3 2025, revenue was 38.22 billion yuan (+5.41%), with a net profit attributable to shareholders of 530 million yuan (+8.46%) [1] - The company's cash flow from operating activities improved, with a net increase of 341 million yuan compared to the same period last year, primarily due to enhanced collection of accounts receivable [1] Strategic Initiatives - The company is deepening its "Three New, Two Transformations" strategy, focusing on new products, new retail, new medical services, and digitalization [2] - The CSO business generated revenue of 14.73 billion yuan in the first three quarters, with pharmaceutical sales of 8.74 billion yuan (+15.26%) [2] - The number of self-operated and franchised pharmacies reached 33,275, with sales revenue from franchise pharmacies at 5.40 billion yuan (+43.40%) [2] - The "Nine Medical Clinics" membership stores reached 3,000, with a target of 10,000 in three years, and over 490 new products introduced in the first three quarters [2] - R&D investment in Q1-Q3 2025 was 229 million yuan, with 1,591 technical personnel, and 34 digital projects implemented [2] Market Position and Valuation - The company maintains a leading position in the out-of-hospital distribution sector, with a projected net profit attributable to shareholders of 2.69 billion yuan, 2.82 billion yuan, and 3.11 billion yuan for 2025-2027, corresponding to a PE ratio of 10, 9, and 8 times [3] - The company is rated as a "Buy" due to its improving cash flow and market leadership [3] Real Estate Securities - The public REIT "Jiuzhoutong R" was successfully listed in February 2025, raising 1.16 billion yuan with a subscription multiple of 1,192 times [2] - The closing price of the Huatai Jiuzhoutong Medical REIT (508084) increased by 43.28% compared to the benchmark price, with a maximum increase of 51.81% during the period [2]

Core Viewpoint - The private pharmaceutical distribution leader, Jiuzhoutong (600998.SH), continues to show steady growth in performance, driven by its "Three New and Two Transformations" strategy, with significant increases in revenue and net profit in the third quarter of 2025 [2] Group 1: Financial Performance - In the first three quarters, Jiuzhoutong achieved revenue of 119.33 billion yuan, a year-on-year increase of 5.20%, and a net profit attributable to shareholders of 1.975 billion yuan, up 16.46% year-on-year [2] - In Q3, the net profit attributable to shareholders and the net profit after deducting non-recurring gains and losses increased by 8.46% and 15.24% year-on-year, respectively [2] - The company reported a quarter-on-quarter net profit growth of 11.39% and a 16.49% increase in net profit after deducting non-recurring gains and losses [2] Group 2: Business Segments - Jiuzhoutong's pharmaceutical distribution business maintained steady growth, while emerging business segments such as drug agency promotion, pharmaceutical manufacturing, and digital logistics saw revenue growth rates of 15.26%, 9.93%, and 24.95%, respectively [2] - The company completed the public REITs issuance for pharmaceutical warehousing and logistics infrastructure, contributing an additional net profit of 438 million yuan [2] Group 3: New Product Strategy - The new product strategy, as part of the "Three New and Two Transformations" strategy, is crucial for the company's future development, with a comprehensive structure established for product strategy [3] - The agency brand promotion business (CSO) generated sales revenue of 14.73 billion yuan in the first three quarters, with a 15.26% year-on-year increase, driven by stable growth in core agency product sales [3] - The company introduced 81 new products in the first three quarters, with 32 star products achieving annual sales exceeding 100 million yuan [3] Group 4: New Retail Strategy - Jiuzhoutong's subsidiary, Haoyao Shi, provided comprehensive B2C e-commerce agency services, achieving sales revenue of 817 million yuan, a year-on-year increase of 13.00% [5] - The number of Haoyao Shi's direct and franchise stores reached 33,275 across 31 provinces and municipalities by the end of Q3 2025 [5] - The franchise sales scale maintained rapid growth, with sales revenue of 5.402 billion yuan, up 43.40% year-on-year [5] Group 5: Digital and New Medical Strategies - Jiuzhoutong's new medical strategy is progressing steadily, with over 3,000 clinic member stores established, aiming for a network of 10,000 clinics within three years [6] - The company has accelerated its digital transformation, particularly in AI development, with R&D investment of 229 million yuan and a technical staff of 1,591 [6] - The company's public REITs, the first in the domestic pharmaceutical industry, performed well in the market, with a cumulative increase of 43.28% since its listing [6]

Core Viewpoint - 九州通 is strategically enhancing its layout in the health industry through investments in various funds and incubators, aiming for sustainable growth and innovation in the medical sector [1][2][3]. Group 1: Strategic Investments - 九州通's subsidiary, 九州众创孵化器, has committed 10 million yuan to establish the Wuhan Chuchang Tongda Industrial Investment Fund, holding a 7.14% stake in the fund [1][2]. - The total investment for the Chuchang Tongda Fund is 140 million yuan, with 九州众创孵化器 contributing 10 million yuan, while other partners include 武汉光创基金 and 北京点金, with respective contributions of 40 million yuan and 88 million yuan [2]. - The focus of these investments is on innovative medical devices, consumer healthcare, life sciences services, and biopharmaceuticals, aligning with the company's strategic goals [2][3]. Group 2: Financial Performance - In the first half of 2025, 九州通 reported revenue of 81.106 billion yuan, a year-on-year increase of 5.10%, and a net profit attributable to shareholders of 1.446 billion yuan, up 19.70% [5][6]. - The company achieved strong growth across various business segments, with pharmaceutical distribution generating 67.634 billion yuan in sales, a 6.04% increase, and digital logistics revenue rising by 24.66% to 5.87 billion yuan [6]. - The cash flow from operating activities increased by 380 million yuan compared to the previous year, indicating a positive outlook for the company's financial health [5][6]. Group 3: Industry Position - 九州通 is recognized as the largest private pharmaceutical enterprise in China and has been listed among the top 500 Chinese enterprises, ranking 181st in the 2025 list with a revenue of 151.8 billion yuan [1][4]. - The company has been focusing on its core business while exploring new retail and digitalization strategies, contributing to its stable growth in a challenging industry environment [5][6].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has shown improvement in cash flow and continues to advance its "Three New and Two Transformations" strategy [8] - In the first half of 2025, the company achieved a revenue of 81.106 billion yuan, representing a year-on-year increase of 5.10%, and a net profit attributable to shareholders of 1.446 billion yuan, up 19.70% year-on-year [8] - The company successfully issued public REITs for pharmaceutical warehousing and logistics, contributing a net profit of 438 million yuan [8] - The report adjusts the net profit forecasts for 2025-2027 to 2.694 billion yuan, 2.818 billion yuan, and 3.108 billion yuan respectively, corresponding to a PE ratio of 10, 9, and 8 times [8] Financial Performance Summary - Total revenue forecast for 2023A is 150.14 billion yuan, with a projected growth of 6.92% [1] - The net profit attributable to shareholders for 2023A is forecasted at 2.174 billion yuan, with a year-on-year growth of 4.27% [1] - The latest diluted EPS for 2023A is estimated at 0.43 yuan per share [1] - The company’s operating cash flow is expected to increase significantly, with a net cash flow from operating activities of 6.75 billion yuan in 2025E [9]

Core Viewpoint - The strategic implementation of "Three New and Two Transformations" has led to steady growth for the pharmaceutical distribution leader, Jiuzhoutong, with significant increases in revenue and net profit in the first half of 2025 [1][2]. Financial Performance - Jiuzhoutong reported a revenue of 81.106 billion yuan, a year-on-year increase of 5.10%, and a net profit attributable to shareholders of 1.446 billion yuan, up 19.70% [1][2]. - The company's core pharmaceutical distribution business generated sales of 67.634 billion yuan, reflecting a growth of 6.04% [3]. - The net cash flow from operating activities increased by 3.8 billion yuan compared to the previous year, indicating improved cash collection efforts [2]. Business Segments Growth - Emerging business segments such as pharmaceutical manufacturing and digital logistics saw rapid growth, with pharmaceutical manufacturing revenue increasing by 10.77% to 1.593 billion yuan and digital logistics revenue rising by 24.66% to 0.587 billion yuan [3][4]. - The new retail business achieved sales of 1.493 billion yuan, with a 41.30% increase in sales to franchise stores [3]. Strategic Initiatives - The company has intensified investments in its "Three New and Two Transformations" strategy, with a focus on new products, new retail, new healthcare, digitalization, and real estate securitization [1][5]. - Jiuzhoutong's investment in talent recruitment under the "Three Flowers" strategy reached 55.2 million yuan, a 110% increase year-on-year [1]. Digital Transformation - Jiuzhoutong invested 146 million yuan in research and development, focusing on AI applications across various business scenarios to enhance operational efficiency [4][6]. - The company successfully launched its public REITs for pharmaceutical warehousing and logistics, raising 1.158 billion yuan, with a subscription multiple of 1192 times, setting a record in the public REITs sector [7]. Market Position and Future Plans - The company aims to expand its retail network, projecting over 33,500 stores by the end of 2025, and plans to establish a network of 10,000 clinics within three years [6]. - Jiuzhoutong's AI-assisted diagnostic platform is being utilized in over 2,400 clinic member stores, with significant monthly usage [6].

Investment Rating - The investment rating for the company is "Buy" [9][16] Core Views - The company's performance in H1 2025 met expectations, with a revenue of 81.11 billion yuan, representing a 5.10% increase year-on-year, and a net profit attributable to shareholders of 1.446 billion yuan, up 19.70% [3][4] - The growth in net profit was primarily driven by steady growth in pharmaceutical distribution revenue and rapid growth in emerging business segments such as pharmaceutical manufacturing and digital logistics, which saw revenue increases of 10.77% and 24.66% respectively [3][6] - The company successfully completed the issuance and listing of public REITs for pharmaceutical warehousing and logistics infrastructure, contributing an additional 438 million yuan to net profit [3][8] - The company is focusing on a digital transformation strategy, with significant investments in AI applications across various business scenarios, enhancing operational efficiency [8] Financial Performance - In H1 2025, the gross profit margin was 7.56%, a decrease of 0.35 percentage points, while the net profit margin increased by 0.22 percentage points to 1.78% [4] - The core pharmaceutical distribution business achieved sales revenue of 67.634 billion yuan, a year-on-year increase of 6.04% [6][13] - The company anticipates revenue growth for 2025-2027 to be 164.05 billion yuan, 177.33 billion yuan, and 191.63 billion yuan respectively, with net profits projected at 2.672 billion yuan, 2.899 billion yuan, and 3.209 billion yuan [9][11] Strategic Initiatives - The company is implementing a "Three New and Two Transformations" strategy, focusing on new products, new retail, new healthcare, and digitalization, with significant investments in talent and operational capabilities [5][8] - The number of franchise stores for the "Good Pharmacist" retail business reached 31,535, with sales to franchise stores amounting to 3.418 billion yuan, a year-on-year increase of 41.30% [6][8]

Core Viewpoint - 九州通 has reported strong financial performance for the first half of 2025, achieving a revenue of 81.106 billion yuan, a year-on-year increase of 5.10%, and a net profit of 1.446 billion yuan, up 19.70%, despite industry challenges [1] Group 1: Financial Performance - The company achieved a revenue of 81.106 billion yuan in H1 2025, reflecting a 5.10% year-on-year growth [1] - The net profit attributable to shareholders reached 1.446 billion yuan, marking a 19.70% increase compared to the previous year [1] Group 2: Strategic Initiatives - 九州通 is focusing on its "Three New and Two Digital" strategy, which includes new products, new retail, new medical services, digitalization, and real estate securitization [2] - The company introduced 61 new pharmaceutical products during the reporting period, with total sales revenue from brand promotion reaching 9.591 billion yuan [2] Group 3: New Retail and Medical Services - The new retail strategy, centered around the "Good Medicine Master" franchise, generated sales revenue of 1.493 billion yuan, a 2.52% increase year-on-year [2] - The number of "Good Medicine Master" stores reached 31,535 by the end of June 2025, with expectations to exceed 33,500 by the end of the year [3] Group 4: Digitalization and AI Integration - 九州通 has developed a SaaS system for clinic management, enhancing operational efficiency with features like rapid patient registration and billing [4] - The company has partnered with Tencent Cloud to create an AI-assisted diagnostic platform, which is currently used in over 1,500 clinics [4] Group 5: Emerging Business Growth - The pharmaceutical manufacturing segment achieved sales of 1.593 billion yuan, a 10.77% increase, while the digital logistics segment reported revenue of 0.587 billion yuan, up 24.66% [7][8] - The medical beauty business generated sales of 0.583 billion yuan, reflecting a significant growth of 48.64% [8] Group 6: ESG and Credit Rating - 九州通 has committed to social responsibility, donating 11.3781 million yuan in the first half of 2025 and receiving various ESG ratings, including "AA" from mainstream ESG rating agencies [9] - The company achieved a AAA credit rating from a leading credit rating agency, marking it as the only AAA-rated private enterprise in the pharmaceutical distribution sector [9]

Core Viewpoint - 九州通 has received an upgrade in its credit rating to AAA with a stable outlook from China Chengxin International Credit Rating Co., Ltd, reflecting the company's strong operational performance and strategic initiatives [1][2]. Group 1: Credit Rating Upgrade - The credit rating agency has issued a report assessing 九州通's credit status, resulting in an upgrade from AA+ to AAA [1]. - The stable outlook indicates confidence in the company's future performance and creditworthiness [1]. Group 2: Reasons for Upgrade - 九州通 has focused on its core business in the pharmaceutical and health sector, successfully advancing its "three new and two transformations" strategy, which includes new products, new retail, new medical services, digitalization, and real estate securitization [2]. - The company has achieved a transformation in its health industry services through digitalization, platformization, and internet integration, establishing a comprehensive pharmaceutical supply chain service platform valued at "hundreds of billions" [2]. - The implementation of an efficient digital financial management model and a rigorous risk control system has strengthened the company's credit quality [2]. Group 3: Implications of the Upgrade - The upgrade to AAA is expected to lower the company's overall financing costs, broaden financing channels, and enhance the liquidity of its bonds [2]. - This rating reflects the capital market's high recognition of 九州通's comprehensive strength and is significant for the company's sustainable and healthy development [2].

Core Viewpoint - The company is transforming its development momentum through the "Three New and Two Transformations" strategy, focusing on digital transformation, new retail, and new medical services to become the most professional health service provider in China and achieve its goal of becoming a century-old enterprise [1][7]. Digital Empowerment - The company has evolved from a grassroots pharmaceutical wholesaler to a technology-driven comprehensive service provider in the pharmaceutical industry, with a clear strategic path and implementation results in its digital transformation [1][2]. - The digital transformation includes collaboration across business, management, and logistics, with a focus on reducing costs and increasing efficiency [2][3]. - The company has achieved a significant reduction in logistics errors, with an error rate controlled at one in a million, enhancing both efficiency and quality [2]. Strategic Focus - The "Three New" strategy addresses the long-standing "two disconnections" in the industry by enhancing control over upstream products and establishing a new retail network for downstream channels [2][5]. - The company aims for new product-related sales to account for 20% of total revenue and 50% of gross profit in the next three years [3][5]. Medical Aesthetics Business - The company is accelerating its layout in the medical aesthetics sector, which has shown rapid growth, increasing from several million to several billion in scale [5][6]. - The medical aesthetics market is seen as a key profit growth point, driven by the aging population and rising consumer demand for beauty services [5][6]. Talent Strategy - The company has shifted its talent acquisition strategy, significantly increasing the recruitment of external senior talent to meet the demands of its strategic transformation [6][7]. - In 2023, the company introduced a "Three Transformations Talent Strategy," aiming to recruit over 300 senior talents annually [6]. Financial Performance - The company's sales revenue has grown from 21.185 billion in 2010 to 151.81 billion in 2024, with a compound annual growth rate of 15.10% [6]. - The net profit attributable to the parent company increased from 360 million in 2010 to 2.507 billion in 2024, with a compound annual growth rate of 14.88% [6].